Compare Enovix Corporation (ENVX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Merck & Co., Inc. — how do they compare? Enovix Corporation trades at $2.47 (market cap $549.72M), while Merck & Co., Inc. trades at $144.73 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 639× Enovix Corporation's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Merck & Co., Inc. for 98 Days on average.
| ENVX | MRK | |
|---|---|---|
Market Cap | $549.72M | $351.28B |
Volume | 6,635,687 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $13.19 | $156.43 |
52-Week Low | $2.50 | $82.49 |
Typical Hold Time | 11 Days | 98 Days |
Enterprise Value | $611.42M | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.46, down 3.53% on the day, reflecting a bearish technical trend. The company is in a high-growth investment phase, with revenue growing to $36 million in 2026 but reporting significant losses. Recent news highlights a CEO transition and progress in battery manufacturing for defense and consumer electronics, while analyst consensus remains largely positive with a $10.75 price target.
The outlook is bifurcated: strong analyst buy ratings and institutional interest signal long-term potential, but high cash burn, persistent losses, and bearish technical indicators present substantial near-term risks. Investment hinges on successful commercialization and achieving profitability from current expansion efforts.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
